Last reviewed · How we verify
Matched transdermal placebo gel
Matched transdermal placebo gel is a Small molecule drug developed by Manchester University NHS Foundation Trust. It is currently FDA-approved.
A matched placebo formulation designed to mimic the appearance, texture, and application method of an active transdermal gel for use as a control in clinical trials.
At a glance
| Generic name | Matched transdermal placebo gel |
|---|---|
| Sponsor | Manchester University NHS Foundation Trust |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
This is a placebo comparator product formulated as a transdermal gel to match an active pharmaceutical agent in a clinical trial setting. It contains no active pharmaceutical ingredient and is used to provide blinding and control in randomized controlled trials conducted by Manchester University NHS Foundation Trust. The matched formulation ensures that trial participants and investigators cannot distinguish the placebo from the active treatment based on sensory characteristics.
Approved indications
Common side effects
Key clinical trials
- Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome (PHASE3)
- Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX) (PHASE2, PHASE3)
- Study of The Effects of Testosterone in Frail Elderly Men (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Matched transdermal placebo gel CI brief — competitive landscape report
- Matched transdermal placebo gel updates RSS · CI watch RSS
- Manchester University NHS Foundation Trust portfolio CI